Streptococcus pyogenes

Recce Pharmaceuticals Granted New Patent in Israel for RECCE® Anti-Infectives

Retrieved on: 
Thursday, April 4, 2024
Escherichia coli, Central Bureau, Statistics, Burn, PCT, Shingles, Biotechnology, Growth, Disease, HIV, Klebsiella pneumoniae, COVID-19, Inhalation, HCMV, ASX, RCE, Recce, Viral, Pseudomonas aeruginosa, Virus, EBV, SARS-CoV-2, Staphylococcus aureus, Gonorrhea, Cytomegalovirus, Ross River virus, Neisseria meningitidis, GDP, Urinary tract infection, Skin, Streptococcus pyogenes, Patent, Staphylococcus, Streptococcus pneumoniae, Simplex, Infection, USD, Administration, Biology, Ageing, Pharmaceutical industry

SYDNEY, Australia, April 04, 2024 (GLOBE NEWSWIRE) -- Recce Pharmaceuticals Ltd (ASX: RCE, FSE: R9Q), the Company developing a new class of synthetic anti-infectives, today announced that the State of Israel Patent Office has formally granted Recce a new family four patent (patent number: 295116), “Process for Preparation of Biologically Active Copolymer Comprising an Acrolein Derivative and a Polyalkylene Glycol Oligomer,” with expiry in 2041.

Key Points: 
  • SYDNEY, Australia, April 04, 2024 (GLOBE NEWSWIRE) -- Recce Pharmaceuticals Ltd (ASX: RCE, FSE: R9Q), the Company developing a new class of synthetic anti-infectives, today announced that the State of Israel Patent Office has formally granted Recce a new family four patent (patent number: 295116), “Process for Preparation of Biologically Active Copolymer Comprising an Acrolein Derivative and a Polyalkylene Glycol Oligomer,” with expiry in 2041.
  • “We are thrilled to have received this newly granted patent in Israel,” said James Graham, Chief Executive Officer of Recce Pharmaceuticals.
  • Israel’s pharmaceuticals and biotechnology market has a reputation for high R&D spending and an impressive international reach, with world-class export numbers and a growing market value.
  • Other examples include influenza A, Ross River virus, and coronaviruses, including those responsible for severe acute respiratory syndrome and SARS-CoV-2 (COVID-19).

Cyrus Biotechnology to Present Its Novel IgG-degrading IdeS Enzyme Development Candidates for Autoimmune Indications at PepTalk Conference in San Diego

Retrieved on: 
Tuesday, January 16, 2024
Software, Biotechnology, Pharmaceutical, Health, Artificial Intelligence, Health Technology, Technology, Clinical Trials, Protein, Streptococcus pyogenes, Multimedia, Half-life, Immunoglobulin G, Autoimmune disease, WT, Disease, Rabbit, Antibody, MHC, Ides, Immunity, Guillain–Barré syndrome, Vaccine

The presentation will take place at the 23rd annual PepTalk conference in San Diego.

Key Points: 
  • The presentation will take place at the 23rd annual PepTalk conference in San Diego.
  • The IgG-degrading enzyme of S. pyogenes (IdeS) has been approved in wild type form for use in certain kidney transplantation recipients, where IgG depletion successfully mitigates host immunity against the transplant.
  • View the full release here: https://www.businesswire.com/news/home/20240116136157/en/
    Figure shows IgG levels after WT IdeS in diamonds and Cyrus’ candidates in squares and triangles.
  • Indications such as Guillain-Barre Syndrome, Autoimmune Immune Thrombocytopenia, Idiopathic Immune Myopathies, pemphigus vulgaris, and other diseases with a poor current standard of care are under consideration.

Recce Pharmaceuticals Granted New Patent in Canada for RECCE® Anti-Infectives

Retrieved on: 
Monday, November 27, 2023
Recce, Ross River virus, Simplex, ASX, Government, RCE, Klebsiella pneumoniae, PCT, Virus, Burn, Administration, Streptococcus pneumoniae, Patent, Disease, Staphylococcus aureus, Infection, Gonorrhea, Canada Revenue Agency, Inhalation, Shingles, Pseudomonas aeruginosa, Biology, COVID-19, Streptococcus pyogenes, Viral, EBV, Escherichia coli, HIV, Coronavirus, SARS-CoV-2, Cytomegalovirus, Staphylococcus, Urinary tract infection, Bacteria, Neisseria meningitidis, HCMV, Science, Skin, Pharmaceutical industry

SYDNEY, Australia, Nov. 27, 2023 (GLOBE NEWSWIRE) -- Recce Pharmaceuticals Limited (ASX: RCE, FSE: R9Q), the Company developing a new class of synthetic anti-infectives, is pleased to announce the Canadian Patent Office has formally granted Recce a new family four patent, “Process for Preparation of Biologically Active Copolymer,” with expiry in 2041.

Key Points: 
  • SYDNEY, Australia, Nov. 27, 2023 (GLOBE NEWSWIRE) -- Recce Pharmaceuticals Limited (ASX: RCE, FSE: R9Q), the Company developing a new class of synthetic anti-infectives, is pleased to announce the Canadian Patent Office has formally granted Recce a new family four patent, “Process for Preparation of Biologically Active Copolymer,” with expiry in 2041.
  • “We thank the Canadian Government for their recognition of the significant potential of Recce’s New Class of Anti-infectives,” said James Graham, Chief Executive Officer of Recce Pharmaceuticals.
  • In July 2023, the Company received an AUD $98,428 R&D Rebate from the Canadian Government, under the Scientific Research & Experimental Development (SR&ED) Tax Incentive program.
  • The program is administered by the Canada Revenue Agency and is aimed at incentivizing businesses to conduct R&D in Canada, encouraging innovation and technological advancements.

Recce Pharmaceuticals Granted New Anti-Viral Patent in Australia for RECCE® Anti-Infectives

Retrieved on: 
Friday, August 4, 2023
Patent, Intellectual property, Inhalation, Australian patent law, Pathogenic bacteria, Conditioned place preference, Cytomegalovirus, HIV, EBV, SARS-CoV-2, Streptococcus pyogenes, Coronavirus, COVID-19, Recce, Gonorrhea, Skin, ASX, FSE, Burn, Staphylococcus, Shingles, Escherichia coli, Severe acute respiratory syndrome outbreak, Streptococcus pneumoniae, Staphylococcus aureus, Klebsiella pneumoniae, Simplex, PCT, Viral disease, Urinary tract infection, Pseudomonas aeruginosa, Administration, Neisseria meningitidis, Biology, Ross River virus, Viral, Infection, Bacteria, Family, Virus, HCMV, Disease, RCE, Pharmaceutical industry, Vaccine, Proteus, Serratia, Enterococcus

SYDNEY, Australia, Aug. 04, 2023 (GLOBE NEWSWIRE) -- Recce Pharmaceuticals Ltd (ASX: RCE, FSE: R9Q), the Company developing a new class of synthetic anti-infectives, is pleased to announce the Australian Patent Office has formally granted Recce a new family four patent, “Process for Preparation of Biologically Active Copolymer,” with expiry in 2041.

Key Points: 
  • SYDNEY, Australia, Aug. 04, 2023 (GLOBE NEWSWIRE) -- Recce Pharmaceuticals Ltd (ASX: RCE, FSE: R9Q), the Company developing a new class of synthetic anti-infectives, is pleased to announce the Australian Patent Office has formally granted Recce a new family four patent, “Process for Preparation of Biologically Active Copolymer,” with expiry in 2041.
  • “We are thrilled to receive this new family of intellectual property, granted by the Australian Patent Office, with further market monopolies reinforcing opportunities among a significant range of bacterial and viral pathogens,” said James Graham, Chief Executive Officer of Recce Pharmaceuticals.
  • Viral infections may be caused by a range of viruses, such as coated viruses (e.g., lipid-coated viruses), including herpes, human immunodeficiency virus (HIV), cytomegalovirus, and influenza.
  • Other examples include Influenza A, Ross River virus, and coronavirus, including those responsible for severe acute respiratory syndrome and SARS-CoV-2 (COVID-19).

Recce Pharmaceuticals to be Granted New Anti-Viral Patent in Australia for RECCE® Anti-Infectives

Retrieved on: 
Tuesday, April 11, 2023
Patent, Inhalation, Australian patent law, Veterans' Preference Act of 1944, Cytomegalovirus, HIV, EBV, SARS-CoV-2, Streptococcus pyogenes, Recce, Gonorrhea, Skin, ASX, FSE, Burn, Staphylococcus, Shingles, Escherichia coli, Severe acute respiratory syndrome outbreak, Streptococcus pneumoniae, Staphylococcus aureus, Klebsiella pneumoniae, Simplex, Varicella zoster virus, PCT, Viral disease, Urinary tract infection, Pseudomonas aeruginosa, Administration, Neisseria meningitidis, Patient, Biology, Ross River virus, Viral, Infection, Bacteria, Virus, HCMV, Disease, RCE, Pharmaceutical industry, Vaccine, Proteus, Serratia, Enterococcus

SYDNEY, Australia, April 11, 2023 (GLOBE NEWSWIRE) -- Recce Pharmaceuticals Ltd (ASX: RCE, FSE: R9Q), the Company developing a new class of synthetic anti-infectives, is pleased to announce the Australian Patent Office issued notification of intent to grant Recce a new family four patent, “Process for Preparation of Biologically Active Copolymer,” with expiry in 2041.

Key Points: 
  • SYDNEY, Australia, April 11, 2023 (GLOBE NEWSWIRE) -- Recce Pharmaceuticals Ltd (ASX: RCE, FSE: R9Q), the Company developing a new class of synthetic anti-infectives, is pleased to announce the Australian Patent Office issued notification of intent to grant Recce a new family four patent, “Process for Preparation of Biologically Active Copolymer,” with expiry in 2041.
  • “We would like to thank the Australian Patent Office for this notification of intent, which further validates the potential of our new class of anti-infectives to help patients with a broad range of bacterial and viral infections,” said James Graham, Chief Executive Officer of Recce Pharmaceutical.
  • Viral infections that may be caused by a range of viruses, such as coated viruses (e.g., lipid-coated viruses), include herpes, human immunodeficiency virus (HIV), cytomegalovirus, and influenza.
  • Other examples include influenza A, Ross River virus, and coronaviruses, including those responsible for severe acute respiratory syndrome.

Dettol Pro Solutions Shares How to Help Prevent Spread of Strep A Via Proper Cleaning Protocols and Product Selection

Retrieved on: 
Wednesday, January 18, 2023
Retail, Health, Chemicals, Plastics, Infectious Diseases, Home Goods, Manufacturing, Supermarket, Disease, Infection, UK Health Security Agency, Urinary tract infection, Scarlet fever, R, Rapid strep test, UKHSA, Sneeze, Security agency, Invasive, Elbow, Virus, Reckitt, Laboratory, Medicine, Streptococcus pyogenes, Severe acute respiratory syndrome coronavirus 2, Skin, Impetigo, Cough, Bacteria, IGAS, GAS, Water, Group A streptococcal infection, Streptococcus, Hygiene, Multimedia, COVID-19, Vaccine, Tissue paper, Dettol

GAS infections often present as a mild sore throat ('strep throat') and skin/soft tissue infections such as impetigo and cellulitis1.

Key Points: 
  • GAS infections often present as a mild sore throat ('strep throat') and skin/soft tissue infections such as impetigo and cellulitis1.
  • Dettol Pro Solutions, which consists of a team of in-house virologists, microbiologists and medical scientists, was launched in the UK last year.
  • Dettol Pro Solutions’ products are demonstrated to kill 99.9% of bacteria and enveloped viruses including Streptococcus A, Covid-19 and Influenza6.
  • For further information and advice from Dettol Pro Solutions, please visit https://www.reckittpro.co.uk .

Protara Therapeutics Announces Trials in Progress Poster Presentation for the ADVANCED-1 Trial in NMIBC at the 23rd Annual Meeting of the Society of Urologic Oncology

Retrieved on: 
Thursday, December 1, 2022
COVID-19, Microcystic lymphatic malformation, United, LM, IL-6, Degenerative disease, Food and Drug Administration, Urology, Granulocyte colony-stimulating factor, TNF, Streptococcus, Food, Safety, LMS, CIS, Therapy, Granulocyte-macrophage colony-stimulating factor, Lymphocyte, Patient, IL-8, Monocyte, Neutrophil, Society, Cytokine, Neoplasm, Date, Annual general meeting, Streptococcus pyogenes, IL-12, Cancer, Cyst, Bladder cancer, FDA, Pharmaceutical industry, Risk management, NMIBC

The ADVANCED-1 study is evaluating TARA-002, an investigational cell-based immunopotentiator, for the treatment of non-muscle invasive bladder cancer (NMIBC).

Key Points: 
  • The ADVANCED-1 study is evaluating TARA-002, an investigational cell-based immunopotentiator, for the treatment of non-muscle invasive bladder cancer (NMIBC).
  • In the initial dose escalation phase of the trial, patients will receive six weekly intravesical doses of TARA-002.
  • Bladder cancer is the 6th most common cancer inthe United States, with NMIBC representing approximately 80% of bladder cancer diagnoses.
  • Protara is committed to identifying and advancing transformative therapies for people with cancer and rare diseases with limited treatment options.

VIRINX Announces the Successful Contactless Suppression of Wound-Infecting Bacteria by its Viper22 System

Retrieved on: 
Tuesday, October 18, 2022
IOT, Prevalence, Wound healing, Staphylococcus, Diagnosis, Infection, Methicillin-resistant Staphylococcus aureus, Candida albicans, Streptococcus pyogenes, Escherichia coli, Multimedia, Risk, Hertz, Company, Acinetobacter baumannii, Spore, CEO, Statista, Patent, Abscess, Bacteria, Enterococcus faecalis, Pseudomonas aeruginosa, Osteomyelitis, View, Pharmaceutical industry, Mobile phone

LAKE FOREST, Calif., Oct. 18, 2022 /PRNewswire/ -- Virinx LLC ("VIRINX" or "the Company"), a developer of highly integrated IoT devices, announced the successful preliminary test results of its Viper22 system, which is a miniature noncontact wound and fungus infection treatment system.

Key Points: 
  • LAKE FOREST, Calif., Oct. 18, 2022 /PRNewswire/ -- Virinx LLC ("VIRINX" or "the Company"), a developer of highly integrated IoT devices, announced the successful preliminary test results of its Viper22 system, which is a miniature noncontact wound and fungus infection treatment system.
  • Appropriate antimicrobial therapy is the cornerstone of successful wound treatment.
  • "VIRINX has previously evaluated the impact of using microwave frequencies of 6 to 10 GHz and exposing bacteria to these microwave frequencies on glass surfaces for few minutes.
  • The bacteria counts were reduced by more than three 10log on glass surfaces," stated Dr. Fred Mohamadi, VIRINX's CEO.

Nabriva Therapeutics to Report Second Quarter 2022 Financial Results and Recent Corporate Highlights on August 3, 2022

Retrieved on: 
Wednesday, July 20, 2022
Regulation of food and dietary supplements by the U.S. Food and Drug Administration, MRSA, Patient, Streptococcus agalactiae, MSSA, Streptococcus anginosus group, Bacteria, Food and Drug Administration, Tablet, Culture, Drug of last resort, Marketing, Pyelonephritis, ABSSSI, Review, Staphylococcus aureus, Infection, Streptococcus constellatus, Diarrhea, U.S. Securities and Exchange Commission, Human, Union, Research, Enterococcus, Merck, Moxifloxacin, Streptococcus intermedius, Private Securities Litigation Reform Act, Urinary tract infection, GLOBE, Streptococcus anginosus, Food, COVID-19, Conference, Nausea, Streptococcus pyogenes, Vomiting, Cutis laxa, Linezolid, Fosfomycin, Enterococcus faecalis, Bronchopneumonia, Complicated, Therapy, NASDAQ, Gram, Cystic fibrosis, Pharmaceutical industry, Streptococcus

ET to discuss the financial results and recent corporate highlights.

Key Points: 
  • ET to discuss the financial results and recent corporate highlights.
  • Nabriva Therapeutics is a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections.
  • Nabriva Therapeutics is also developing CONTEPO (fosfomycin) for injection, a potential first-in-class epoxide antibiotic for complicated urinary tract infections (cUTI), including acute pyelonephritis.
  • However, while Nabriva Therapeutics may elect to update these forward-looking statements at some point in the future, it specifically disclaims any obligation to do so.

Protara Therapeutics Announces Trials in Progress Poster Presentation for the ADVANCED-1 Trial in NMIBC at the 2022 American Society of Clinical Oncology Annual Meeting

Retrieved on: 
Thursday, May 26, 2022
Online, Cancer, U.S. Securities and Exchange Commission, TNF, Private Securities Litigation Reform Act, Food, Streptococcus pyogenes, LMS, Bladder cancer, Nasdaq, Food and Drug Administration, Patient, Cyst, Therapy, IL-8, Degenerative disease, Cytokine, Microcystic lymphatic malformation, Society, CIS, IFN, COVID-19, LM, Streptococcus, FDA, Neutrophil, Industry, Granulocyte-macrophage colony-stimulating factor, Safety, Neoplasm, NMIBC, Lymphocyte, IL-12, Monocyte, IL-6, Granulocyte colony-stimulating factor, United, GLOBE, Medical imaging, Pharmaceutical industry

The ADVANCED-1 study is evaluating TARA-002, an investigational cell-based immunopotentiator, for the treatment of non-muscle invasive bladder cancer (NMIBC).

Key Points: 
  • The ADVANCED-1 study is evaluating TARA-002, an investigational cell-based immunopotentiator, for the treatment of non-muscle invasive bladder cancer (NMIBC).
  • We look forward to continuing to advance this trial and exploring TARA-002s full potential in NMIBC.
  • In the initial dose escalation phase of the trial, patients will receive six weekly intravesical doses of TARA-002.
  • Bladder cancer is the 6th most common cancer inthe United States, with NMIBC representing approximately 80% of bladder cancer diagnoses.